The 'Rizzoli Score': An Easy Prognostic Score for Survival Estimation for Patients with Symptomatic Long Bone Metastases

2020 ◽  
Author(s):  
Costantino Errani ◽  
Monica Cosentino ◽  
Giovanni Ciani ◽  
Lorenzo Ferra ◽  
Patricio Alfaro ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Prognostic Score ◽  
Long Bone ◽  
Survival Estimation

An Easy-to-Use Prognostic Model for Survival Estimation for Patients with Symptomatic Long Bone Metastases

2018 ◽  
Vol 100 (3) ◽  
pp. 196-204 ◽  
Author(s):  
J.J. Willeumier ◽  
Y.M. van der Linden ◽  
C.W.P.G. van der Wal ◽  
P.C. Jutte ◽  
J.M. van der Velden ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Prognostic Model ◽  
Long Bone ◽  
Survival Estimation

Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e17026-e17026
Author(s):  
Sara Elena Rebuzzi ◽  
Matteo Bauckneht ◽  
Alessio Signori ◽  
Viviana Frantellizzi ◽  
Elisa Lodi Rizzini ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Peripheral Blood ◽  
Scoring System ◽  
Prognostic Score ◽  
Clinical Factors ◽  
Prognostic Role ◽  
Internal Validation ◽  
Prognostic Groups ◽  
Ecog Ps

e17026 Background: Ra-223 is a treatment option for mCRPC pts with bone metastases according to the survival benefit observed compared to placebo in the ALSYMPCA trial. In the last years, many studies showed this benefit in the real-life pts is lower than that reported in the trial, probably due to a suboptimal selection of pts with poor prognostic characteristics. Therefore, the identification of prognostic factors to select mCRPC pts most likely to benefit from Ra-223 is needed. The multicentre retrospective BIO-Ra-223 study has investigated the prognostic role of peripheral blood immune cells and clinical factors to develop a novel prognostic score for mCRPC pts treated with Ra-223. Methods: Complete blood count was assessed before Ra-223 treatment calculating neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII). Clinical factors included pre-treatment Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason Score (GS) group, number of bone metastases, alkaline phosphatase (ALP), line of therapy, previous chemotherapy and the presence of lymphadenopathies. Statistical analyses included survival ROC curves for biomarkers’ cutoffs, univariable and multivariable Cox analyses, internal validation, c-index calculation and Schneeweiss scoring system. Results: From September 2013 to July 2020, 519 mCRPC pts received Ra-223 as 1st-2nd, 3rd-4th and further-line in 48%, 38% and 14% of pts. The median overall survival (mOS) of the entire cohort was 19.9 months. All biomarkers and clinical factors (except for GS group) significantly predicted OS at the univariable analyses. In the multivariable ones, all biomarkers, ECOG PS, number of bone metastases and ALP significantly correlated with OS. The multivariable model with NLR (< 3.1 vs ≥3.1), ECOG PS (0-1 vs 2-3), number of bone metastases (< 6, 6-20, > 20) and ALP (< 220 vs ≥220) showed the highest c-index (0.711), which was maintained after internal validation (bootstrap re-sampling) (c-index: 0.707). Using the Schneeweiss scoring system, ten categories were identified in 494 pts with complete data and merged in two prognostic groups with distinctive OSs: group 1 (score 0-4, 337 pts) with a mOS of 27.8 months and group 2 (score 5-10, 157 pts) with a mOS of 9.7 months (HR 4.03, p < 0.001). Conclusions: The obtained score, composed of NLR, ECOG PS, number of bone metastases, and ALP identifies two distinctive prognostic groups of mCRPC pts. Moreover, this score is easily and widely applicable for clinical practice and trials at no additional costs. Although external validation is needed, these preliminary results showed that this novel prognostic score is promising and could help the patients’ selection for Ra-223 treatment.

Intramedullary Nails for Long Bone Metastases: Why Do They Fail?

Orthopedics ◽  
2011 ◽  
Author(s):  
Benjamin J. Miller ◽  
Emily E. Carmody Soni ◽  
C. Parker Gibbs ◽  
Mark T. Scarborough
Keyword(s):  
Bone Metastases ◽  
Long Bone ◽  
Intramedullary Nails

scholarly journals High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases

2018 ◽  
Vol 476 (10) ◽  
pp. 2052-2061 ◽  
Author(s):  
Olivier Q. Groot ◽  
Paul T. Ogink ◽  
Stein J. Janssen ◽  
Nuno Rui Paulino Pereira ◽  
Santiago Lozano-Calderon ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
High Risk ◽  
Bone Metastases ◽  
Long Bone

Indications for the Surgical Treatment of Long Bone Metastases

2006 ◽  
pp. 133-146 ◽  
Author(s):  
Rodolpho Capanna ◽  
Domenico A. Campanacci
Keyword(s):  
Surgical Treatment ◽  
Bone Metastases ◽  
Long Bone

Treatment for long bone metastases based on a systematic literature review

2016 ◽  
Vol 27 (2) ◽  
pp. 205-211 ◽  
Author(s):  
Costantino Errani ◽  
Andreas F. Mavrogenis ◽  
Luca Cevolani ◽  
Silvia Spinelli ◽  
Andrea Piccioli ◽  
...  
Keyword(s):  
Literature Review ◽  
Bone Metastases ◽  
Systematic Literature Review ◽  
Long Bone

scholarly journals Should post-operative radiation for long bone metastases cover part or all of the orthopaedic hardware? Results of a large retrospective analysis

2021 ◽  
pp. 100756
Author(s):  
Daniel B. Rosen ◽  
Justin M. Haseltine ◽  
Meredith Bartelstein ◽  
Jessica R. Flynn ◽  
Zhigang Zhang ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Retrospective Analysis ◽  
Long Bone

scholarly journals 2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates?

2015 ◽  
Vol 473 (10) ◽  
pp. 3112-3121 ◽  
Author(s):  
Stein J. Janssen ◽  
Andrea S. van der Heijden ◽  
Maarten van Dijke ◽  
John E. Ready ◽  
Kevin A. Raskin ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Long Bone ◽  
Young Investigator ◽  
Young Investigator Award ◽  
Boosting Algorithm
Sign in / Sign up

Export Citation Format

Share Document